Renub Research

Page 1 of 12

United States OffLabel Drugs Market Analysis

Offlabel prescribing of medicines is prevalent worldwide because it gives freedom to
physicians to apply new therapeutic options based on the latest evidence. Although physicians
may lawfully prescribe approved Drugs for any use consistent with available scientific data and
proper medical practice, but unfortunately, this is done without adequate scientific data.
Often, when the best available therapeutic option fails, patients demand new approach or new
treatment which ultimately leads to offlabel uses.
Offlabel use is very common in United States. United States Offlabel Drugs demand has grown
at a fast pace in the past decade and likely to grow in the forecasting period. It is likely that
United States offlabel market will cross the figure of 60 Billion by the year 2020. Central
Nervous System (CNS) and Cancer offlabel Drugs controls the largest market share of the total
US offlabel Drugs market. AntiInfectives OffLabel Drugs Market and AntiAshmatics OffLabel
Drugs together are expected to control close to 35% market share by 2020.
Renub Research study titled United States OffLabel Drugs Market & Forecast report
provides a comprehensive analysis of the emerging OffLabel Drugs market. The report also
entails

commonly

prescribed

OffLabel

Drugs,

Perspective

of

Physicians,

Patients,

Pharmaceutical Companies and Regulatory Authorities, Offlabel Promotion Settlements under

the False Claims Act. The report also studies Drivers and Challenges of United States OffLabel
Drugs market. This 67 page report with 16 Figures and 1 Table studies 6 OffLabel Drugs
Segment.
The 6 OffLabel Drugs Segment Covered in the Report are as Follows:
1. Cancer OffLabel Drugs
2. Central Nervous System (CNS) OffLabel Drugs
3. AntiAshmatics OffLabel Drugs
4. AntiAllergies OffLabel Drugs
5. AntiHypertensives OffLabel Drugs
6. AntiInfectives OffLabel Drugs

Renub Research

Page 2 of 12

Data Sources
This report is built using data and information sourced from proprietary databases, primary and
secondary research and inhouse analysis by Renub Research team of industry experts.
Primary sources include industry surveys and telephonic interviews with industry experts.
Secondary sources information and data has been collected from various printable and non
printable sources like search engines, News websites, Government Websites, Trade Journals,
White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books,
Industry Portals, Industry Associations and access to more than 500 paid databases.

Renub Research

Page 3 of 12

About Us
Renub Research

is a leading Market Research and Information Analysis Company with

centers at Noida India and Roswell USA. We have longterm experience especially in
international BusinesstoBusiness Researches, Surveys, Business and Consulting. Throughout
the years we have acquired expertise in most market sectors, including Information Technology
(IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial Services (Banking,
Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive, Retail, FMCG, Consumer
Goods, Logistics, Governmental, Social, and Others.
Our core team is comprised of an experienced people holding graduate, post graduate and
Ph.D. degrees in Finance, Marketing, Human Resource, BioTechnology, Medicine, Information
Technology, Environmental Science and many more. Our research help make the business
decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We
support many blue chip companies by providing them findings and perspectives across a wide
range of markets. Our research reports offer a blend of information insight, analysis and
forecasting that is essential in todays ultracompetitive markets.

For more information on us or to view any of our sample work you can mail
us at info@renub.com

Renub Research

Page 4 of 12

Published
By

Renub Research
1st Floor,
C86, Sector10
Noida 201301
Phone: +911204219822, 2545750 (India)
+16783020700 (USA)
Fax : +911204249780
Email: info@renub.com
www.renub.com

United States OffLabel Drugs Market & Forecast

Renub Research, 2015
Edition 1.0
All rights reserved. This publication is protected
by copyright. No part of it may be reproduced, stored
in a retrieval system or transmitted, in any form or by
any means, electronic mechanical, photocopying,
recording or otherwise without the prior written
permission of the publishers

Renub Research

Page 5 of 12

Table of Contents
1.

Executive Summary

2.

United States OffLabel Drugs Market & Forecast

3.

United States OffLabel Drugs Market Share & Forecast

4.

United States OffLabel Drugs Market Segment wise

4.1

United States Cancer OffLabel Drugs Market & Forecast

4.2

United States Central Nervous System (CNS) OffLabel Drugs Market & Forecast

4.3

United States AntiAshmatics OffLabel Drugs Market & Forecast

4.4

United States AntiAllergies OffLabel Drugs Market & Forecast

4.5

United States AntiHypertensives OffLabel Drugs Market & Forecast

4.6

United States AntiInfectives OffLabel Drugs Market & Forecast

5.

Drugs Commonly Prescribed OffLabel

6.

OffLabel Use of Medicine & Different Perspectives

6.1

Physicians Perspective

6.1.1

7.

Physicians Liability for OffLabel Prescriptions

6.2

Patients Perspective

6.3

Perspective of the Pharmaceutical Companies

6.4

Perspective of Regulatory Agencies

OffLabel Promotion Settlements Under The False Claims Act

7.1

Year 2004

7.2

Year 2005

7.3

Year 2006

7.4

Year 2007

7.5

Year 2008

7.6

Year 2009

7.7

Year 2010

7.8

Year 2011

Renub Research

Page 6 of 12

8.

9.

7.9

Year 2012

7.10

Year 2013

7.11

Year 2014

United States OffLabel Drugs Market Growth Drivers

8.1

Clinical Practices and Application in the OffLabel Drugs

8.2

Vulnerable Patient Populations: Information and Access

8.3

OffLabel Promotion Reform

United States OffLabel Drugs Market Challenges

9.1

Lack of Regulation & Information of the United States OffLabel Drugs Market

9.2

Reimbursement

9.3

Safety and Efficacy of Unapproved and Under Evaluated Use

9.4

Point of View on Bioethical OffLabel Drugs Use

9.5

Inaccuracy of OffLabel Clinical Publications

Renub Research

Page 7 of 12

List of Figures
Figure 21: United States OffLabel Drugs Market (Billion US$), 2011 2014
Figure 22: United States Forecast for OffLabel Drugs Market (Billion US$), 2015 2020
Figure 31: United States OffLabel Drugs Market Share (Percent), 2011 2014
Figure 32: United States Forecast for OffLabel Drugs Market Share (Percent), 2015 2020
Figure 41: United States Cancer OffLabel Drugs Market (Billion US$), 2008 2014
Figure 42: United States Forecast for Cancer OffLabel Drugs Market (Billion US$), 2015 2020
Figure 43: United States Central Nervous System (CNS) OffLabel Drugs Market (Billion US$), 2009
2014
Figure 44: United States Forecast for Central Nervous System (CNS) OffLabel Drugs Market (Billion
US$), 2015 2020
Figure 45: United States AntiAshmatics OffLabel Drugs Market (Billion US$), 2010 2014
Figure 46: United States Forecast for AntiAshmatics OffLabel Drugs Market (Billion US$), 2015
2020
Figure 47: United States AntiAllergies OffLabel Drugs Market (Billion US$), 2011 2014
Figure 48: United States Forecast for AntiAllergies OffLabel Drugs Market (Billion US$), 2015 2020
Figure 49: United States AntiHypertensives OffLabel Drugs Market (Billion US$), 2009 2014
Figure 410: United States Forecast for AntiHypertensives OffLabel Drugs Market (Billion US$), 2015
2020
Figure 411: United States AntiInfectives OffLabel Drugs Market (Billion US$), 2008 2014
Figure 412: United States Forecast for AntiInfectives OffLabel Drugs Market (Billion US$), 2015
2020

Renub Research

Page 8 of 12

List of Tables
Table 51: Commonly Prescribed OffLabel Drugs

Renub Research

Page 9 of 12

Order Form
Scan and e-mail this page to info@renub.com, alternatively one can also write the Contact
Information in an e-mail and mail it. Else you can also fax this form to +91-120-424-9780
Questions? Please call

+91-120-421-9822 (India),

+1-678-302-0700

(USA)

or

mail

info@renub.com

Format
Report Title: United States OffLabel Drugs Market & Forecast

Single User
(Email from Publisher)

Hard Copy
(Mail Delivery)

CD Rom
(Mail Delivery)

Global Site License

(Multiple User License)

US$ 1,200

US$ 1,300

US$ 1,300

US$ 1,800

For ordering this report: Three easy ways to place your order:
1) Order online by Credit Card (Visa, MasterCard, etc.):
http://www.renub.com/report/united-states-off-label-drugs-market-forecast-163
2) Order by Wire Transfer:
http://www.renub.com/report/wiretransfer.aspx?id=163&pid=1625

To pay by Wire Transfer, please, fill in your contact details in the form below:

Renub Research

Page 10 of 12

to

Bank Details
Account Name: Renub Research
A/C No.: 109102000023296
Name of Bank: IDBI Bank Ltd.
Swift Code: IBKLINBB010
Bank Address: 4th Floor
Indian Red Cross Building
1 Red Cross Road
Opposite Parliament Street
New Delhi 110001
India

Contact Information
First Name:

Last Name:

Email:
Job Title:
Company:
Address:
City:
Postal/Zip Code:
Country:
Phone:
Mobile:
Fax:
Report Format:
Your message:

Renub Research

Page 11 of 12

3) Order by Check
Please post the check accompanied by this form, to:
Company Address: Renub Research
1st Floor
C-86, Sector -10
Noida - 201301
Uttar Pradesh
India
Phone: +91-120-421-9822, 424-9780

For free Sample copy report or to view any of our sample work please contact us at
info@renub.com or call +91-120-421-9822 (India), +1-678-302-0700 (USA)

Follow Us
Facebook: http://www.facebook.com/pages/Renub-Research/233380966701090
LinkedIn: http://www.linkedin.com/company/renub-research
Twitter: http://twitter.com/RenubResearch

Renub Research

Page 12 of 12